Genomic alterations involved in fluoroquinolone resistance development in Staphylococcus aureus

PLoS One. 2023 Jul 26;18(7):e0287973. doi: 10.1371/journal.pone.0287973. eCollection 2023.

Abstract

Aim: Fluoroquinolone (FQ) is a potent antibiotic class. However, resistance to this class emerges quickly which hinders its application. In this study, mechanisms leading to the emergence of multidrug-resistant (MDR) Staphylococcus aureus (S. aureus) strains under FQ exposure were investigated.

Methodology: S. aureus ATCC 29213 was serially exposed to ciprofloxacin (CIP), ofloxacin (OFL), or levofloxacin (LEV) at sub-minimum inhibitory concentrations (sub-MICs) for 12 days to obtain S. aureus -1 strains and antibiotic-free cultured for another 10 days to obtain S. aureus-2 strains. The whole genome (WGS) and target sequencing were applied to analyze genomic alterations; and RT-qPCR was used to access the expressions of efflux-related genes, alternative sigma factors, and genes involved in FQ resistance.

Results: A strong and irreversible increase of MICs was observed in all applied FQs (32 to 128 times) in all S. aureus-1 and remained 16 to 32 times in all S. aureus-2. WGS indicated 10 noticeable mutations occurring in all FQ-exposed S. aureus including 2 insdel mutations in SACOL0573 and rimI; a synonymous mutation in hslO; and 7 missense mutations located in an untranslated region. GrlA, was found mutated (R570H) in all S. aureus-1 and -2. Genes encoding for efflux pumps and their regulator (norA, norB, norC, and mgrA); alternative sigma factors (sigB and sigS); acetyltransferase (rimI); methicillin resistance (fmtB); and hypothetical protein BJI72_0645 were overexpressed in FQ-exposed strains.

Conclusion: The emergence of MDR S. aureus was associated with the mutations in the FQ-target sequences and the overexpression of efflux pump systems and their regulators.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins / genetics
  • Ciprofloxacin / pharmacology
  • Fluoroquinolones / pharmacology
  • Genomics
  • Humans
  • Microbial Sensitivity Tests
  • Staphylococcal Infections*
  • Staphylococcus aureus* / genetics

Substances

  • Fluoroquinolones
  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Bacterial Proteins

Grants and funding

This study was financially supported by The Youth Incubator for Science and Technology Programme, managed by Youth Promotion Science and Technology Center - Ho Chi Minh Communist Youth Union and Department of Science and Technology of Ho Chi Minh City, under the contract number 34/2022/ HĐ-KHCNT-VU. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.